Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777338 | 0.90 | CCNC (0.41) | CCNCCDK8MIFMEN1KMT2A | |
| SCHEMBL5773927 | 0.90 | CCNC (0.41) | CCNCCDK8MIFMEN1KMT2A | |
| SCHEMBL5775587 | 0.90 | CCNC (0.41) | CCNCCDK8MIFMEN1KMT2A | |
| SCHEMBL5773931 | 0.86 | CYP11B1 (0.44) | CCNCCDK8MEN1KMT2APPARA | |
| SCHEMBL5774825 | 0.85 | FFAR1 (0.42) | CCNCCDK8PPARAFFAR1 | |
| SCHEMBL5776590 | 0.84 | PPARA (0.47) | CCNCCDK8MEN1KMT2APPARA | |
| SCHEMBL5773378 | 0.84 | CYP11B1 (0.45) | CCNCCDK8CYP11B1CYP11B2MAPT | |
| SCHEMBL5776699 | 0.83 | NOTUM (0.44) | CCNCCDK8MEN1KMT2ATP53 | |
| SCHEMBL5776982 | 0.83 | MAPK1 (0.44) | CCNCCDK8MEN1KMT2AMAPK1 | |
| SCHEMBL5773406 | 0.82 | CCNC (0.44) | CCNCCDK8MEN1KMT2APPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | CCNC 3936/4885CDK8 3280/4885MIF 3361/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | CCNC 3879/4885CDK8 3137/4885MIF 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.